by the time next repport with small float and most share in 3 holders hands. 17 million plus 7 million on balance sheet is 24 million witth bigh growth and 0 debt. At current sp, market cap is 110 million and vext years sales in 55 million rannge which is 2x sales. most biotechs are 7-11x sales which makes it quite undervalued
